{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:36:06Z","timestamp":1776828966576,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007044","name":"sociedade portuguesa de nefrologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007044","id-type":"DOI","asserted-by":"publisher"}]},{"name":"sociedade portuguesa de transplanta\u00e7\u00e3o"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00223-021-00910-8","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:04:45Z","timestamp":1630713885000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Role of Bone Volume, FGF23 and Sclerostin in Calcifications and Mortality; a Cohort Study in CKD Stage 5 Patients"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1323-5293","authenticated-orcid":false,"given":"Ana Carina","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Patr\u00edcia","family":"Cotovio","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Aires","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Mendes","sequence":"additional","affiliation":[]},{"given":"David","family":"Navarro","sequence":"additional","affiliation":[]},{"given":"Cec\u00edlia","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Caeiro","sequence":"additional","affiliation":[]},{"given":"Rute","family":"Salvador","sequence":"additional","affiliation":[]},{"given":"Bruna","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Guadalupe","family":"Cabral","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Nolasco","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-6033","authenticated-orcid":false,"given":"An\u00edbal","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"23","key":"910_CR1","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","volume":"341","author":"RA Wolfe","year":"1999","unstructured":"Wolfe RA, Ashby VB, Milford EL et al (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341(23):1725\u20131730","journal-title":"N Engl J Med"},{"issue":"5","key":"910_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S2213-8587(14)70059-2","volume":"2","author":"MG Vervloet","year":"2014","unstructured":"Vervloet MG, Massy ZA, Brandenburg VM et al (2014) Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol 2(5):427\u2013436","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"910_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.semnephrol.2014.02.007","volume":"34","author":"P Evenepoel","year":"2014","unstructured":"Evenepoel P, Rodriguez M, Ketteler M (2014) Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease? Semin Nephrol 34(2):151\u2013163","journal-title":"Semin Nephrol"},{"issue":"11","key":"910_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945\u20131953","journal-title":"Kidney Int"},{"issue":"2","key":"910_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1053\/j.ajkd.2012.07.022","volume":"61","author":"HM Alshayeb","year":"2013","unstructured":"Alshayeb HM, Josephson MA, Sprague SM (2013) CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis 61(2):310\u2013325","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"910_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.ki.5002769","volume":"73","author":"FC Barreto","year":"2008","unstructured":"Barreto FC, Barreto DV, Moyses RM et al (2008) K\/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 73(6):771\u2013777","journal-title":"Kidney Int"},{"issue":"7","key":"910_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3747\/pdi.2014.00246","volume":"34","author":"EJ Lamb","year":"2014","unstructured":"Lamb EJ, Delaney MP (2014) Does PTH offer additive value to ALP measurement in assessing CKD-MBD? Perit Dial Int 34(7):687\u2013691","journal-title":"Perit Dial Int"},{"issue":"4","key":"910_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1053\/j.ajkd.2015.11.028","volume":"67","author":"A Covic","year":"2016","unstructured":"Covic A, Voroneanu L, Apetrii M (2016) PTH and\/or bone histology: are we still waiting for a verdict from the CKD-MBD grand jury? Am J Kidney Dis 67(4):535\u2013538","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"910_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Bellorin-Font E, Jorgetti V et al (2016) Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67(4):559\u2013566","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"910_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00467-015-3069-7","volume":"31","author":"VM Brandenburg","year":"2016","unstructured":"Brandenburg VM, D\u2019Haese P, Deck A et al (2016) From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol 31(2):195\u2013206","journal-title":"Pediatr Nephrol"},{"key":"910_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/1471-2369-14-219","volume":"14","author":"VM Brandenburg","year":"2013","unstructured":"Brandenburg VM, Kramann R, Koos R et al (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219","journal-title":"BMC Nephrol"},{"issue":"6","key":"910_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM, Mannstadt M, Isakova T et al (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359(6):584\u2013592","journal-title":"N Engl J Med"},{"issue":"6","key":"910_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/sdi.12415","volume":"28","author":"RM Moyses","year":"2015","unstructured":"Moyses RM, Schiavi SC (2015) Sclerostin, osteocytes, and chronic kidney disease - mineral bone disorder. Semin Dial 28(6):578\u2013586","journal-title":"Semin Dial"},{"issue":"6","key":"910_CR14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/ndt\/gfh217","volume":"19","author":"T Adragao","year":"2004","unstructured":"Adragao T, Pires A, Lucas C et al (2004) A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 19(6):1480\u20131488","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"910_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster DW, Compston JE, Drezner MK et al (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(1):2\u201317","journal-title":"J Bone Miner Res"},{"key":"910_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab081","author":"R Neto","year":"2021","unstructured":"Neto R, Pereira L, Magalh\u00e3es J et al (2021) SCLEROSTIN AND DKK1 CIRCULATING LEVELS ASSOCIATE WITH LOW BONE TURNOVER IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGES 3 AND 4. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfab081","journal-title":"Clin Kidney J"},{"issue":"12","key":"910_CR17","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/ndt\/gft222","volume":"28","author":"G Jean","year":"2013","unstructured":"Jean G, Chazot C (2013) Sclerostin in CKD-MBD: one more paradoxical bone protein? Nephrol Dial Transplant 28(12):2932\u20132935","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"910_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1210\/jc.2013-2786","volume":"99","author":"D Cejka","year":"2014","unstructured":"Cejka D, Marculescu R, Kozakowski N et al (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99(1):248\u2013255","journal-title":"J Clin Endocrinol Metab"},{"key":"910_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2013.10.019","volume":"59","author":"MM Roforth","year":"2014","unstructured":"Roforth MM, Fujita K, McGregor UI et al (2014) Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 59:1\u20136","journal-title":"Bone"},{"issue":"5","key":"910_CR20","doi-asserted-by":"publisher","first-page":"e19595","DOI":"10.1371\/journal.pone.0019595","volume":"6","author":"D Zhu","year":"2011","unstructured":"Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE 6(5):e19595","journal-title":"PLoS ONE"},{"issue":"15","key":"910_CR21","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1073\/pnas.1221255110","volume":"110","author":"ZC Ryan","year":"2013","unstructured":"Ryan ZC, Ketha H, McNulty MS et al (2013) Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci USA 110(15):6199\u20136204","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"910_CR22","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1681\/ASN.2007010068","volume":"18","author":"S Liu","year":"2007","unstructured":"Liu S, Quarles LD (2007) How fibroblast growth factor 23 works. J Am Soc Nephrol 18(6):1637\u20131647","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"910_CR23","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121(11):4393\u20134408","journal-title":"J Clin Invest"},{"issue":"6","key":"910_CR24","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/ki.2013.3","volume":"83","author":"JJ Scialla","year":"2013","unstructured":"Scialla JJ, Lau WL, Reilly MP et al (2013) Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 83(6):1159\u20131168","journal-title":"Kidney Int"},{"key":"910_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/JAHA.116.003486","volume":"5","author":"R Haring","year":"2016","unstructured":"Haring R, Enserro D, Xanthakis V et al (2016) Plasma fibroblast growth factor 23: clinical correlates and association with cardiovascular disease and mortality in the Framingham heart study. J Am Heart Assoc 5:7","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"910_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2215\/CJN.01870408","volume":"4","author":"T Adragao","year":"2009","unstructured":"Adragao T, Herberth J, Monier-Faugere MC et al (2009) Low bone volume\u2013a risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol 4(2):450\u2013455","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"910_CR27","doi-asserted-by":"publisher","first-page":"e0179868","DOI":"10.1371\/journal.pone.0179868","volume":"12","author":"T Adragao","year":"2017","unstructured":"Adragao T, Ferreira A, Frazao JM et al (2017) Higher mineralized bone volume is associated with a lower plain X-Ray vascular calcification score in hemodialysis patients. PLoS ONE 12(7):e0179868","journal-title":"PLoS ONE"},{"issue":"2","key":"910_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/ndt\/gfu301","volume":"30","author":"C Drechsler","year":"2015","unstructured":"Drechsler C, Evenepoel P, Vervloet MG et al (2015) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30(2):288\u2013293","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"910_CR29","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1093\/ndt\/gft039","volume":"28","author":"L Viaene","year":"2013","unstructured":"Viaene L, Behets GJ, Claes K et al (2013) Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 28(12):3024\u20133030","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"910_CR30","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1210\/jc.2013-1521","volume":"98","author":"KJ Claes","year":"2013","unstructured":"Claes KJ, Viaene L, Heye S, Meijers B, d\u2019Haese P, Evenepoel P (2013) Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 98(8):3221\u20133228","journal-title":"J Clin Endocrinol Metab"},{"key":"910_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1471-2369-15-190","volume":"15","author":"FL Goncalves","year":"2014","unstructured":"Goncalves FL, Elias RM, dos Reis LM et al (2014) Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 15:190","journal-title":"BMC Nephrol"},{"issue":"6","key":"910_CR32","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/ki.2015.194","volume":"88","author":"AR Qureshi","year":"2015","unstructured":"Qureshi AR, Olauson H, Witasp A et al (2015) Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 88(6):1356\u20131364","journal-title":"Kidney Int"},{"issue":"9","key":"910_CR33","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S et al (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183\u20133193","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00910-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-021-00910-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00910-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T16:03:02Z","timestamp":1642953782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-021-00910-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["910"],"URL":"https:\/\/doi.org\/10.1007\/s00223-021-00910-8","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Besides receiving a grant from the Portuguese Society of Nephrology and the Portuguese Society of Transplantation\/Astellas, we do not have any conflict of interest relating with this manuscript. The results presented in this paper have not been published previously in whole or part, except in abstract format.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutions\u2019 local ethics committees approved this study. Written consent was obtained from all participants prior to entering the protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}